HC Andersen Capital: NeoDynamics - Magnus Precht on Pulse technology in the US market
NeoDynamics’ Magnus Precht updates us on the US market. On Tuesday 1st of March 2022, NeoDynamics filed a registration application for its innovative Pulse biopsy system NeoNavia® with the US Food and Drug Administration, FDA.
Read the press release here.
We have interviewed Magnus Precht to explain the characteristics of the US Market. Watch the interview here.
At NeoDynamics, Magnus will lead the commercialization in the US market. In the interview, Magnus presents his experiences within the US market, the Pulse technology with its innovative platform, as well as the registration application to the FDA. NeoNavia is already CE-approved in Europe and is in clinical use.
Magnus also talks about why the US market is so important to NeoDynamics.
The global breast biopsy market is expected to reach $ 1.66 billion by 2025, with a CAGR of 8.7% during the period 2021-2025. The global incidence of breast cancer in 2020 was about 2.3 million new cases. An increasing prevalence, rising female population over 65 years, and emerging adoption of liquid biopsy are contributing factors behind the growth. This is further enhanced by the growing awareness of breast biopsy. The US market for breast cancer diagnostics is crucial for NeoDynamics. The market accounts for almost 50% of global breast biopsies.
NeoDynamics is a Swedish medical technology company that works to improve the treatment and diagnosis of cancer. The company's first product is NeoNavia, which is a modern biopsy system with a completely new and patented pulse technology that is intended to be used for ultrasound-guided tissue sampling. The NeoNavia pulse biopsy system is designed to offer physicians and patients accurate and reliable tissue sampling that enables accurate diagnosis and individualized treatment. NeoNavia is being evaluated for the diagnosis of breast cancer at leading clinics in the UK, Germany, and Sweden.
This is a press release from HC ANDERSEN CAPITAL https://hcandersencapital.dk